老年急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后延长应用替格瑞洛对临床转归的影响
CSTR:
作者:
作者单位:

(1.秦皇岛市第一医院 心血管内科,河北 秦皇岛 066099;2.秦皇岛市第一医院老年病科,河北 秦皇岛 066099)

作者简介:

通讯作者:

中图分类号:

基金项目:

秦皇岛市科技计划(201805A096)


Effect of prolonged ticagrelor on clinical outcomes in elderly patients with acute ST-segment elevation myocardial infarction after percutaneous coronary intervention
Author:
Affiliation:

(1.Department of Cardiology, Qinhuangdao 066099, Hebei Province, China;2.Department of Geriatrics, Qinhuangdao First Hospital, Qinhuangdao 066099, Hebei Province, China)

Fund Project:

This work was supported by Qinhuangdao Science and Technology Plan (201805A096).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨老年(年龄≥65岁)急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后延长应用替格瑞洛对临床转归的影响。方法 纳入2018年2月至2021年2月在秦皇岛市第一医院行PCI后接受替格瑞洛+阿司匹林双联抗血小板治疗(DAPT)的≥65岁急性STEMI患者105例(应用DAPT评分系统评估均≥2分),在阿司匹林长期用药基础上,根据患者服用替格瑞洛时间不同分为对照组(n=37,使用时间为PCI治疗后1年)与观察组(n=68,在对照组基础上再延长替格瑞洛治疗1年),其中观察组根据延长应用替格瑞洛的剂量不同又分为2个亚组,即观察A组(n=40,标准剂量, 90mg/次,每日2次)和观察B组(n=28,小剂量,45mg/次,每日2次)。比较3组患者急诊PCI术后心肌梗死溶栓治疗(TIMI)3级血流、心电图完全回落比例、血栓弹力图中的血小板功能(MA)、二磷酸腺苷诱导的血小板聚集率;随访1年,主要不良心脑血管事件(MACCE)、出血事件发生情况。采用SPSS 25.0软件进行数据分析。根据数据类型,组间比较采用t检验、χ2检验。结果 PCI术后,观察A、B组的TIMI 3级血流患者比例显著高于对照组(χ2=4.699、4.353;P=0.030、0.036),而观察A组与观察B组组间差异无统计学意义。PCI治疗后2年,观察A、B组血栓弹力图中的MA值、二磷酸腺苷诱导的血小板聚集率明显低于对照组(t=8.752、6.524;均P<0.001),但观察A组、观察B组比较差异无统计学意义。随访1年,3组总MACCE发生率比较差异有统计学意义(χ2=4.354;P=0.039),其中观察组A、B组MACCE发生率均显著低于对照组(χ2=4.769、5.082;P=0.028、0.024),但观察A组与观察B组间差异无统计学意义;3组患者出血事件发生率差异均无统计学意义。结论 老年(≥65岁)STEMI患者(DAPT评分≥2分)PCI后延长应用替格瑞洛可能降低主要不良心脑血管事件发生率,且小剂量(45mg/次)替格瑞洛并未增加出血发生的风险,仍需长期随访观察进一步证实。

    Abstract:

    Objective To investigate the effect of prolonged ticagrelor on clinical outcomes after percutaneous coronary intervention (PCI) in the elderly patients (age≥65 years) with acute ST-segment elevation myocardial infarction (STEMI). Methods From February 2018 to February 2021, a total of 105 patients (aged≥65 years) with acute STEMI were enrolled, who received dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin (DAPT≥2) after PCI at the First Hospital of Qinhuangdao. On the basis of long-term use of aspirin, the patients were divided into the control group (n=37; ticagrelor for one year) and the observation group (n=68; ticagrelor over one year). The observation group was divided into two subgroups according to the dose of ticagrelor:observation group A (n=40; standard dose, 90 mg/time, 2 times daily) and observation group B (n=28; low dose, 45 mg/time, 2 times daily). The three groups were compared after emergency PCI in thrombolysis in myocardial infarction (TIMI) grade 3 blood flow, proportion of complete regression of electrocardiogram (ECG) signs, platelet function (MA) in thrombelastogram (TEG), adenosine diphosphate-induced platelet aggregation rate, and 1-year follow-up, including major adverse cardiovascular and cerebrovascular events (MACCE) and bleeding events. SPSS 25.0 was used to process the data, and t test andχ2 test were used for comparison between groups. Results After PCI, the proportion of patients with TIMI grade 3 blood flow in the two observation groups was significantly higher than that in the control group (χ2=4.699,4.353; P=0.030,0.036). At two years after PCI, the MA value and adenosine diphosphate-induced platelet aggregation rate on thromboelastography of the two observation groups were significantly lower than those in the control group (t=8.752,6.524; P<0.001). After one year follow-up, there was significant difference in the incidence of MACCE among the three groups (χ2=4.354; P=0.039). The incidence of MACCE in the two observation groups was significantly lower than that in the control group (χ2=4.769,5.082; P=0.028,0.024), but there was no significant difference between the two observation groups. There was no significant difference in the incidence of bleeding events among the three groups. Conclusion Prolonged ticagrelor after PCI in the elderly (≥65 years old) STEMI patients (DAPT≥2 points) may reduce the incidence of MACCE, and low-dose (45 mg) ticagrelor does not increase the risk of bleeding, which needs to be further confirmed with long-term follow-up.

    参考文献
    相似文献
    引证文献
引用本文

任琳,王倩,陈皓,赵甲彧,马利祥.老年急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后延长应用替格瑞洛对临床转归的影响[J].中华老年多器官疾病杂志,2024,23(3):202-206
DOI:10.11915/j. issn.1671-5403.2024.03.043

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-06-12
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-03-22
  • 出版日期:
文章二维码